Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK1IPV)

Drug Name

Ibrexafungerp Drug Info

Synonyms

SCY-078

Indication

Disease Entry	ICD 11	Status	REF
Vulvovaginal Candidiasis	1F23.10	Approved	[1]
Invasive candidiasis	1F23	Phase 3	[2]
Fungal infection	1F29-1F2F	Phase 2	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Fungal 1,3-beta-glucan synthase (Fung GSC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caspofungin	DMGQIPT	Candidiasis	1F23	Approved	[5]
Micafungin	DM6Y3AN	Aspergillosis	1F20	Approved	[6]
Rezafungin	DMQ4CSX	Candidiasis	1F23	Approved	[7]
Anidulafungin	DM8QM5U	Aspergillosis	1F20	Approved	[8]
L-733560	DMYZPJU	Aspergillosis	1F20	Terminated	[9]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fungal 1,3-beta-glucan synthase (Fung GSC2)	TT0SFXH	FKS2_YEAST	Inhibitor	[4]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214900.
2	ClinicalTrials.gov (NCT03059992) Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI). U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031918)
4	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74.
7	Antifungal drugs: What brings the future?. Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343.
8	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
9	Discovery of Novel Antifungal (1,3)--d-Glucan Synthase Inhibitors